- CBT with exposure and response prevention and serotonin reuptake inhibitors are first-line treatments for childhood and adolescent anxiety disorders and OCD.
- Antipsychotic augmentation may be considered for youth who remain significantly symptomatic despite optimised psychosocial, behavioural, and SRI treatment.
- Potential benefits must be balanced with substantial metabolic, neurological, and other risks; careful patient selection, dosing, and monitoring guided by evidence is essential.
Child Adolesc Psychiatr Clin N Am. 2027 Jan;36(1):113-125. doi: 10.1016/j.chc.2026.07.005. Epub 2026 Sep 3.
ABSTRACT
Anxiety disorders and obsessive-compulsive disorder (OCD) are common, impairing conditions in children and adolescents, with first-line management centered on cognitive-behavioral therapy with exposure/response prevention and serotonin reuptake inhibitors (SRIs). A subset of youth remain significantly symptomatic despite optimized psychosocial, behavioral and SRI treatment, prompting consideration for antipsychotic augmentation, particularly in those with refractory OCD and with comorbid tic disorders. Potential benefits must be weighed against substantial risks. This article reviews the evidence base, and practical considerations for antipsychotic use in pediatric anxiety disorders and OCD, and offers guidance on patient selection, dosing, and monitoring.
PMID:43051727 | DOI:10.1016/j.chc.2026.07.005
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

